FibroBiologics (FBLG) Announces $25M Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
FibroBiologics Announces $25 Million Financing
December 23, 2024 7:55 AM ESTHOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the SEPA) with YA II PN LTD. (Yorkville), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
... More


